COMPASS Pathways Is Filing an NDA for Psilocybin. The FDA Priority Vouchers Were the Signal.

On April 24, 2026 — the same day SAMHSA issued its letter defunding fentanyl test strips — the FDA Commissioner awarded National Priority Vouchers to three companies developing psychedelic therapies. The timing was not symbolic. The juxtaposition was.

COMPASS Pathways, the UK-based company behind COMP360 (synthetic psilocybin), received one of those vouchers for its treatment-resistant depression program. The voucher accelerates FDA review from the standard 10-12 months to approximately 6 months. COMPASS has now hit primary endpoints in two consecutive Phase 3 trials — COMP005 in June 2025 and COMP006 in February 2026 — and has targeted a rolling NDA submission in Q4 2026. If the timeline holds, an FDA decision is possible by late 2027, making it the fastest-ever regulatory pathway for a Schedule I compound.

Usona Institute, developing psilocybin for major depressive disorder, and Transcend Therapeutics, developing methylone for PTSD, also received vouchers on April 24. FDA Commissioner Marty Makary told reporters the agency expects to issue a decision on at least one psychedelic therapy “by late summer or fall” — a reference to the accelerated review timelines.

The addiction angle: the primary indication for both COMP360 and Usona’s compound is depression, not substance use disorder. But the separation is more academic than clinical. Psilocybin’s effects on addiction have been documented in earlier Phase 2 trials. A Johns Hopkins study of psilocybin-assisted therapy for tobacco cessation showed 67% abstinence at 12 months — a figure that dwarfs standard pharmacotherapy for nicotine dependence. NYU trials for alcohol use disorder found significant reductions in heavy drinking at six months. The neural mechanisms — psilocybin’s action on 5-HT2A receptors, its disruption of default mode network hyperactivity associated with rumination and craving — are directly relevant to SUD pathophysiology.

What FDA approval doesn’t solve: the delivery problem. Psilocybin-assisted therapy requires a trained therapist, a controlled clinical environment, and 6-8 hours of facilitated care. The drug itself costs pennies. The infrastructure doesn’t. The Center for Psychedelic and Consciousness Research at Johns Hopkins estimates a full treatment course at $3,000–$6,000, primarily personnel costs. Insurance coverage is undefined; no existing CPT code applies. FDA approval without a reimbursement pathway creates an approved treatment that exists primarily for people who can pay out of pocket.

For Arizona, this is both a distant and a concrete question. The state’s $1.215 billion in opioid settlement funds creates a possible financing mechanism for novel treatment approaches — but only once the delivery model is sufficiently defined for state agencies to fund it. That definition is still years away. What should happen now: treatment providers and policy staff tracking this space need to begin the planning work before FDA approval, not after, so that Arizona isn’t scrambling to build infrastructure when the drug becomes available.

The field is moving fast. The financing and delivery infrastructure is not moving at the same speed. That gap is the story of psychedelic therapy in 2026.